SecBot SecBot
SECBOTREPLAY Home › Report › GRFS

GRFS · Grifols announced first patient dosing in two Phase 3 trials (SIGMA and…

Grifols, S.A. · PRESS-RELEASE filed Jul 16, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jul 16, 2026 at 08:00 ET

Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immunoglobulin products GAMUNEX-C (IVIg) and XEMBIFY (SCIg) into secondary immunodeficiency and CIDP, respectively. The trials are early-stage with no near-term financial impact; the company highlighted XEMBIFY's 60% YoY growth in 2025 as a tailwind for the franchise.

  • First patients dosed in two Phase 3 trials: SIGMA (GAMUNEX-C for SID in hematologic cancers) and XPERT (XEMBIFY for CIDP non-inferiority vs GAMUNEX-C).
  • XEMBIFY grew nearly 60% year over year in 2025, indicating strong demand for the SCIg product.
  • SIGMA targets a population of >1 million U.S. patients with CLL, MM, and NHL; XPERT targets ~60,000 U.S. CIDP patients.
  • Both trials are open-label, multicenter studies with small sample sizes (50 and 40 patients respectively).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access